Targacept Works to Develop Drug Candidate for Overactive Bladder

Targacept is planning a Phase IIb study of its experimental drug — TC-5214 — as a treatment for overactive bladder in the first half of next year. The drug developer and partner AstraZeneca had scrapped plans to develop TC-5214 as a potential adjunct treatment for patients for major depressive disorder who didn’t respond adequately to initial antidepressant treatment after the drug didn’t meet primary Phase III study goals late last year.
Fox Business